Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients (Q73356010)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 November 2000

Language	Label	Description	Also known as
English	Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients	scientific article published on 01 November 2000

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

based on heuristic

inferred from title

author name string

F Goldwasser

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M Gross-Goupil

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

J M Tigaud

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M Di Palma

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

J Marceau-Suissa

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

E Wasserman

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

A Yovine

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

J L Misset

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

E Cvitkovic

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 November 2000

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1463-1470

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026535824044

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1026535824044

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142487%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73356010&oldid=1756672705"